関節痛治療の世界市場-2023年～2030年

関節痛の概要

関節痛は関節の痛みとしても知られています。関節痛は、腰、肩、肘、手首、手、膝、足首、足など、体のあらゆる関節に影響を及ぼす可能性があります。関節痛の原因には、関節炎、滑液包炎、腱炎、使いすぎによる損傷、痛風、その他の炎症性疾患など、さまざまな疾患や状態があります。特に、関節痛は、パクリタキセル、ブレオマイシン、クラドリビン、L-アスパラギナーゼのような特定のがん化学療法や薬剤、生物学的反応修飾薬の副作用によって引き起こされることがあります。

さらに、関節痛の治療には、イブプロフェン、ナプロキセン、インドメタシンなどの非ステロイド性抗炎症薬、抗生物質、鎮痛薬、疾患修飾性抗リウマチ薬（DMARDs）、コルチコステロイド、ヒアルロン酸代用薬、カルシウムやビタミンDのサプリメントは骨量減少を防ぐために使用され、アロプリノールは酵素阻害薬などの栄養補助食品が含まれます。代替運動療法としては、水療法や温冷罨法療法も検討されています。

市場力学：促進要因

新規治療薬に対する需要の増加

関節痛治療のための新規治療薬に対する需要の増加は、予測期間にわたって市場を牽引すると予想されます。関節痛に対しては、生物学的療法、理学療法、生活習慣への介入など、非侵襲的かつ非薬物療法への嗜好が高まっています。このような嗜好は、少ない副作用で効果的な緩和をもたらす新規治療オプションの需要に寄与しています。

例えば、2022年3月、CVサイエンシズは、変形性関節症や関節痛の治療に使用される+PlusCBD Relief Softgelsと呼ばれるCBD製品のウェルネスラインの新製品を発表しました。CVサイエンシズによると、この製品は、オリジナルの＋PlusCBD生処方の7倍のCBDAとCBDを供給し、また、エンドカンナビノイド系に影響を与える能力を持ち、イブプロフェンなどの非ステロイド性抗炎症薬と同様の効果があることが調査で示されているレバゲン＋PEA（パルミトイルエタノールアミド）を特徴としています。

さらに、関節痛治療においてより良い結果を示す新規治療薬の開発のために、多くの臨床試験が行われています。新しい分子や標的療法の発見を含む医薬品の研究開発の進歩が、関節痛の新規治療薬の開発を後押ししています。これらの進歩は、より効果的で特異的な治療選択肢を提供します。

例えば、2022年12月、Lupin Ltd.は、関節痛治療薬のジェネリック医薬品を発売しました。は、米国Horizon Pharma Therapeutics社のPENNSAID（ジクロフェナクナトリウム外用液）2％w／wの正規ジェネリック医薬品を発売しました。PENNSAID（ジクロフェナクナトリウム外用液）は、痛風、関節痛、変形性関節症などの炎症性疾患の治療に使用され、膝などの関節の痛みを和らげます。

また、規制当局の承認は、新規治療薬の開発に対する患者の信頼を高める。製薬会社とテクノロジー企業とのコラボレーションにより、創薬と医薬品開発における人工知能と機械学習の統合が実現します。このようなコラボレーション主導のイノベーションは、有効性と効率性を高めた新規治療薬をもたらします。

さらに、関節痛性筋炎の有病率の増加、FDA承認の増加、臨床試験の増加、治療オプションと治療法における認知度の向上と技術の進歩は、予測期間にわたって市場を促進すると予想される要因です。

阻害要因

NSAIDsやその他の薬剤に伴う合併症や副作用、治療費の高騰、ジェネリック医薬品との競合の増加、代替治療オプションの利用可能性などの要因が、市場の阻害要因になると予想されます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 新規治療薬に対する需要の増加
  • 抑制要因
    • 非ステロイド性抗炎症薬の使用に伴う合併症
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析
• パイプライン分析
• アンメットニーズ
• 特許分析
• ボリューム分析
• DMIオピニオン

第6章 COVID-19分析

第7章 治療タイプ別

• 鎮痛薬
• 非ステロイド性抗炎症薬（NSAIDs）
• 抗生物質
• 疾患修飾性抗リウマチ薬（DMARDs）
• ヒアルロン酸代替品
• その他

第8章 流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局

第9章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋地域
• 中東・アフリカ

第10章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A分析

第11章 企業プロファイル

• Mallinckrodt plc
  • 会社概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な発展
• BASF Corporation
• GlaxoSmithKline plc
• KD Pharma Group SA
• Teva Pharmaceuticals USA, Inc.
• LGM Pharma
• Elam Pharma Pvt. Ltd.
• Amar Healthcare
• Bayer AG
• Mayne Pharma Group Limited

第12章 付録

Overview

Arthralgia is also known as joint pain. It can affect any joint in the body, including the hips, shoulders, elbows, wrists, hands, knees, ankles, and feet. Many different diseases and conditions can cause arthralgia, including arthritis, bursitis, tendinitis, overuse injuries, gout, and other inflammatory conditions. Especially, arthralgias may be caused due to side effects of certain cancer chemotreatments and medications such as paclitaxel, bleomycin, cladribine, and L-asparaginase as well as biological response modifiers

Further, the treatment of arthralgia includes NSAIDs like ibuprofen, naproxen, or indomethacin, antibiotics, analgesics, disease-modifying antirheumatic drugs (DMARDs), corticosteroids, hyaluronic acid substitutes and nutritional supplements like Calcium and Vitamin D supplements are used to prevent bone loss and Allopurinol is an enzyme inhibitor and other treatments. Alternative exercise therapies include water therapy and heat and cold fomentation therapy is also considered.

Market Dynamics: Drivers

Increasing demand for novel therapeutics

The increasing demand for novel therapeutics for the treatment of arthralgia is expected to drive the market over the forecast period. There is an increasing preference for non-invasive and non-pharmacological treatments for arthralgia, such as biologic therapies, physical therapy, and lifestyle interventions. This preference contributes to the demand for novel therapeutic options that provide effective relief with fewer side effects.

For instance, in March 2022, CV Sciences introduced a new product to its Wellness line of CBD products called + PlusCBD Relief Softgels used for the treatment of osteoarthritis or arthralgia. According to CV Sciences, the product delivers seven times more CBDA and CBD than the original + PlusCBD raw formula and also features Levagen + PEA (palmitoylethanolamide), which has the ability to influence the endocannabinoid system and has been shown in research to be similarly effective to NSAIDs, such as ibuprofen.

Moreover, many clinical trials are going on for the development of novel therapeutics that show better results in arthralgia treatment. Advances in pharmaceutical research and development, including the discovery of new molecules and targeted therapies, are driving the development of novel therapeutics for arthralgia. These advancements offer more effective and specific treatment options.

For instance, in December 2022, Lupin Ltd. Launched an authorized generic version of PENNSAID (Diclofenac Sodium Topical Solution) 2 percent w/w of Horizon Pharma Therapeutics in the United States. PENNSAID (diclofenac sodium topical solution) is used for the treatment of inflammatory diseases like gout, arthralgia and osteoarthritis to relieve pain in the knee and other joints.

In addition, the regulatory approvals increase the trust in patients about the development of novel therapeutics. Collaborations between pharmaceutical companies and technology firms result in the integration of artificial intelligence and machine learning in drug discovery and development. This collaboration-driven innovation brings about novel therapeutics with enhanced effectiveness and efficiency.

Further, the increasing prevalence of arthralgia myositis, rising FDA approvals, increasing clinical trials, increasing awareness and technological advancements in the treatment options and therapies are the factors expected to drive the market over the forecast period.

Restraints

Factors such as complications and the side effects associated with NSAIDs and other drugs, the high cost of the treatment, increasing competition from generic drugs and availability of alternative treatment options are expected to hamper the market.

Segment Analysis

The global arthralgia treatment market is segmented based on treatment type, distribution channel and region.

The non-steroidal anti-inflammatory drugs (NSAIDs) segment accounted for approximately 48.2% of the arthralgia treatment market share

The non-steroidal anti-inflammatory drugs (NSAIDs) segment is expected to hold the largest market share over the forecast period. Nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, aspirin or naproxen and others are most commonly used and may help relieve pain and swelling for arthralgia patients. NSAIDs are drugs known to provide effective pain relief by inhibiting the production of prostaglandins, which are substances in the body that contribute to pain and inflammation.

Moreover, these drugs are available both over-the-counter (OTC) and by prescription. NSAIDs come in various formulations, including oral tablets, capsules, topical creams or gels, and injectable forms, their wide availability, acceptability, and, ease of application helps to hold the largest market share. In addition, their wide adoption also increases the demand for the NSAIDs.

Geographical Analysis

North America accounted for approximately 39.7% of the market share

North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and advanced healthcare facilities. North America especially the United States is very well-known for its strong presence of major players such as pharmaceutical companies, biotechnology companies and medical device companies. The presence of major players involves performing research activities to develop more advanced treatment options and alternative treatment options for arthralgia.

For instance, on June 26, 2023, Genesys Spine launched the Siros O Oblique SI Fusion system. This is the third sacroiliac joint fusion system offered by Genesys Spine and provides physicians with expanded surgical options to address SI Joint pain.

Moreover, the region is also known for its advanced healthcare facilities using advanced treatment options. The advanced healthcare infrastructure in the region including hospitals, specialty clinics, academic and research institutes and others, this presence of advanced healthcare infrastructure helps to provide advanced treatment facilities for the treatment of arthralgia. Even many FDA approvals are going on in the region for many advanced devices and other therapeutics.

For instance, in July 2023, Medical technology company Motive Health officially introduced Motive Knee, its US Food and Drug Administration (FDA)-approved stimulation device. The knee pain relief device was previously available on a prescription but it can now be ordered by customers without a prescription. Motive Knee has been clinically validated to alleviate knee discomfort and improve mobility by strengthening the knee by leveraging stimulation technology.

Competitive Landscape

The major global players in the arthralgia treatment market include: Mallinckrodt plc, BASF Corporation, GlaxoSmithKline plc, KD Pharma Group SA, Teva Pharmaceuticals USA, Inc., LGM Pharma, Elam Pharma Pvt. Ltd., Amar Healthcare, Bayer AG and Mayne Pharma Group Limited among others.

Key Developments

• On July 11, 2023, Kneeflow utilized a 3-in-1 therapy method with soft massage airbags, infrared light and heat to provide deeper penetration into joints, cartilage and tissue for more effective pain relief, recovery and increased mobility in 10-15-minute sessions. Kneeflow is an at-home, personalized massaging device that can help with the recovery process, prevention and joint pain relief.
• On July 16, 2021, GSK Consumer Healthcare launched the Iodex Rapid Action Spray, a body pain relief solution for modern-day consumers. Iodex now has an exhaustive portfolio of pain relief products such as Iodex Balm, Iodex UltraGel & Iodex Rapid Action Spray, which can cater to different pain states & address varied format preferences of consumers. It has a formula of five active ingredients, namely Indian Wintergreen Oil, Menthol, Eucalyptus oil, Turpentine oil and Clove oil. The blend of ingredients with known analgesic properties helps provide targeted relief from different types of joint pains.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the global arthralgia treatment market. Many clinical trials and research activities for new arthralgia treatments or therapies may have been delayed or temporarily disrupted due to the redirected focus on the COVID-19 pandemic and its related restrictions. This can affect the timelines for the introduction of novel treatments to the market. The pandemic also disrupted the supply chain of these treatment drugs globally.

Why Purchase the Report?

• To visualize the global arthralgia treatment market segmentation based on treatment type, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of arthralgia treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global arthralgia treatment market report would provide approximately 53 tables, 50 figures, and 187 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Treatment Type
• 3.2. Snippet by Distribution Channel
• 3.3. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing Demand for Novel Therapeutics
  • 4.1.2. Restraints
    • 4.1.2.1. Complications Associated with the Use of NSAIDs
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Pipeline Analysis
• 5.6. Unmet Needs
• 5.7. Patent Analysis
• 5.8. Volume Analysis
• 5.9. DMI Opinion

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID
  • 6.1.2. Scenario During COVID
  • 6.1.3. Scenario Post COVID
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Treatment Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 7.1.2. Market Attractiveness Index, By Treatment Type
• 7.2. Analgesics*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
• 7.4. Antibiotics
• 7.5. Disease-Modifying Antirheumatic Drugs (DMARDs)
• 7.6. Hyaluronic Acid Substitutes
• 7.7. Others

8. By Distribution Channel

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 8.1.2. Market Attractiveness Index, By Distribution Channel
• 8.2. Hospital Pharmacies*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Retail Pharmacies
• 8.4. Online Pharmacies

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.2.5.1. U.S.
    • 9.2.5.2. Canada
    • 9.2.5.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.5.1. Germany
    • 9.3.5.2. UK
    • 9.3.5.3. France
    • 9.3.5.4. Italy
    • 9.3.5.5. Spain
    • 9.3.5.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.4.5.1. Brazil
    • 9.4.5.2. Argentina
    • 9.4.5.3. Rest of South America
• 9.5. Asia-Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.5.5.1. China
    • 9.5.5.2. India
    • 9.5.5.3. Japan
    • 9.5.5.4. Australia
    • 9.5.5.5. Rest of Asia-Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

• 11.1. Mallinckrodt plc*
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Financial Overview
  • 11.1.4. Key Developments
• 11.2. BASF Corporation
• 11.3. GlaxoSmithKline plc
• 11.4. KD Pharma Group SA
• 11.5. Teva Pharmaceuticals USA, Inc.
• 11.6. LGM Pharma
• 11.7. Elam Pharma Pvt. Ltd.
• 11.8. Amar Healthcare
• 11.9. Bayer AG
• 11.10. Mayne Pharma Group Limited

LIST NOT EXHAUSTIVE

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us